Ginger Gregory - 10 Feb 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Feb 2022, 15:27:52 UTC
Prior SEC filing
21 Jan 2022
Next SEC filing
15 Feb 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Wendell Taylor, attorney in fact for Ginger Gregory

Key filing fact

Ginger Gregory filed Form 4 for BIOGEN INC. (BIIB) on 14 Feb 2022.

Key facts

  • This page summarizes Ginger Gregory's Form 4 filing for BIOGEN INC. (BIIB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 14 Feb 2022, 15:27.

Change

  • Previous filing in this sequence was filed on 21 Jan 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIIB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,028
Date
10 Feb 2022
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIIB transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+6,475
Change %
Price
$0.000000
Shares after
6,475
Date
10 Feb 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,475
Exercise price
$0.000000
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .